Dara Djafarian

CEO & Board Member, Melio Peptide Systems Inc.

Dara Djafarian is an operator and board member commercializing industrial sustainability, synthetic biology and agri-food technologies.

Dara is currently the CEO and Director of Melio Peptide Systems and a Director of Creatus Biosciences. Prior to this he was at Vanedge Capital, a $140mn venture capital fund focused on technology investments.

Most recently, Dara led Melio to a deal that is set to remove antibiotics from major industrial processes and target antibiotic resistance in the environment and human & animal health.

Dara has a background in operations, governance, technology development and fundraising. He is also experienced in IP asset development, having led filings of over 30 patents globally (with 8 currently granted), and has led deals involving extensive IP and patent portfolios.

Dara received his MSc from University College London (UCL) and BA&Sc from McGill University.